TG Therapeutics, Inc. reported significant financial progress in its latest quarterly filing for the period ending March 31, 2025. The company generated total revenue of $120.9 million, a substantial increase from $63.5 million in the same period last year. This growth was primarily driven by product revenue from BRIUMVI, which amounted to $119.7 million, compared to $50.5 million in the prior year. The company also reported a net income of $5.1 million, a notable turnaround from a net loss of $10.7 million in the first quarter of 2024.
The financial performance reflects a strategic shift following the commercial launch of BRIUMVI in January 2023. The increase in product revenue is attributed to greater market penetration and the successful execution of the commercialization strategy. However, license, milestone, royalty, and other revenue decreased to $1.2 million from $13 million, primarily due to the absence of a significant milestone payment that was recognized in the previous year. The cost of revenue also rose to $15.5 million from $5.4 million, reflecting increased royalties and manufacturing costs associated with BRIUMVI.
Operationally, TG Therapeutics has expanded its workforce, with 352 employees as of May 5, 2025. The company continues to invest in its commercial infrastructure to support the ongoing marketing and sales of BRIUMVI, which has received regulatory approvals in both the U.S. and Europe. The company is also advancing its pipeline, including the development of azer-cel, an allogeneic CAR T cell therapy for autoimmune diseases, which is currently in Phase 1 trials.
Looking ahead, TG Therapeutics anticipates that its cash and cash equivalents, along with projected revenues from BRIUMVI, will provide sufficient liquidity for more than a year. However, the company acknowledges the potential need for additional capital to support ongoing operations and development efforts. The management remains focused on maintaining regulatory approvals and expanding the market presence of BRIUMVI while navigating the complexities of the biopharmaceutical landscape, including competition and regulatory challenges.
About TG THERAPEUTICS, INC.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.